Allianz Asset Management
CSTL icon

Allianz Asset Management’s Castle Biosciences CSTL Stock Holding History

Allianz Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Buy
879,258
+67,934
+8% +$1.51M 0.02% 723
2026
Q1 		$19.9M Buy
811,324
+189,025
+30% +$6.19M 0.02% 616
2025
Q4 		$24.2M Sell
622,299
-26,052
-4% -$840K 0.02% 527
2025
Q3 		$14.8M Sell
648,351
-65,391
-9% -$1.33M 0.02% 688
2025
Q2 		$14.6M Buy
713,742
+74,265
+12% +$1.37M 0.02% 686
2025
Q1 		$12.8M Buy
639,477
+317,103
+98% +$7.85M 0.02% 717
2024
Q4 		$8.59M Buy
322,374
+251,821
+357% +$7.67M 0.01% 802
2024
Q3 		$2.01M Buy
+70,553
New +$1.8M ﹤0.01% 1407
2020
Q2 		– Sell
-29,319
Closed -$874K – 2414
2020
Q1 		$874K Buy
+29,319
New +$885K ﹤0.01% 1849

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Allianz Asset Management's CSTL Position: Q2 2026 in Review

Allianz Asset Management increased its Castle Biosciences (CSTL) stake by 8.4% in Q2 2026, buying an estimated $1.51M and bringing the position to 879,258 shares worth $21M. The position accounts for 0.02% of the portfolio, ranked #723.

Allianz Asset Management first reported a position in CSTL in Q1 2020 and has held it in 9 quarters since. The position peaked at $24.2M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Allianz Asset Management held 879,258 shares of Castle Biosciences worth $21M as of Q2 2026.
  • Allianz Asset Management bought 67,934 Castle Biosciences shares in Q2 2026, an estimated $1.51M.
  • Castle Biosciences made up 0.02% of Allianz Asset Management's portfolio in Q2 2026, its #723 holding.
  • Allianz Asset Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 9 quarters since.
  • Allianz Asset Management's Castle Biosciences position peaked at $24.2M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.